Clinical Trial Update: A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oxaliplatin, capecitabine, and trastuzumab with chemoradiotherapy as adjuvant therapy in operable HER2-positive gastric or gastroesopha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Status: COMPLETED